VJHemOnc is committed to improving our service to you

SOHO 2020 | An update of CAR T-cell therapies in lymphoma

VJHemOnc is committed to improving our service to you

Sattva S Neelapu

Sattva S Neelapu, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, outlines updates in CAR T-cell therapies in lymphoma. Specifically discussed is the CAR-T construct, axicabtagene ciloleucel, which is approved for the treatment of relapsed/refractory large B-cell lymphoma on the basis of the ZUMA-1 trial (NCT02348216), as well as the outcomes of the JULIET (NCT02445248) & TRANSCEND (NCT02631044) studies. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter